MERZ NEUROSCIENCES ANNOUNCES NATIONWIDE AVAILABILITY OF NEW 200-UNIT VIAL OF XEOMIN® (incobotulinumtoxinA). New Vial Size Supports Adult Upper Limb Spasticity Indication

Merz Neurosciences, a division of Merz North America (U.S. affiliate of the global Merz Pharma Group), today announced the nationwide availability of Xeomin® (incobotulinumtoxinA) in a 200-unit single-dose vial. This new dosage size supports the dosing associated with the recently approved adult upper limb spasticity indication for Xeomin® (incobotulinumtoxinA). Xeomin® (incobotulinumtoxinA) is now available to healthcare providers in the US in three single-dose vial sizes: 50 unit, 100 unit and 200 unit, with the same price per toxin unit for all three sizes. Each vial size has a different color label, stopper and top to promote ease of use.

In particular, the new 200 unit vial of Xeomin® (incobotulinumtoxinA) offers convenience for treating adult patients with movement disorders such as upper limb spasticity and cervical dystonia. Additionally, Xeomin® (incobotulinumtoxinA) does not require refrigeration prior to reconstitution and unopened vials can be shipped and stored at room temperature for up to 36 months, offering flexible storage options for healthcare practices.

“It is our hope that the availability of multiple vial options for Xeomin® (incobotulinumtoxinA) may minimize dosing waste and reduce patient out-of-pocket costs,“ said Glenn Block, Vice President and US Head of Merz Neurosciences. “The release of our 200-unit single dose vial of Xeomin® (incobotulinumtoxinA) represents Merz’s ongoing committment to improving the experience of movement disorder patients and physicians.“

Xeomin® (incobotulinumtoxinA) is approved by the U.S. FDA for the treatment of adults with upper limb spasticityand cervical dystonia and to treat blepharospasm in adults who have had prior treatment with onabotulinumtoxinA (Botox®). Today, Xeomin® (incobotulinumtoxinA) is available in 49 countries across the globe. Over one million patients worldwide have been treated with Xeomin® (incobotulinumtoxinA).

About XEOMIN® (incobotulinumtoxinA)

Xeomin® (incobotulinumtoxinA) is a prescription medicine that is injected into muscles and used to treat increased muscle stiffness in the arm of adults with upper limb spasticity, the abnormal head position and neck pain that happens with

cervical dystonia (CD) in adults, and to treat abnormal spasm of the eyelids (blepharospasm) in adults who have had prior treatment with onabotulinumtoxinA (Botox®).

About Merz Neurosciences

Merz Neurosciences is a division of Merz North America, a specialty healthcare company that is dedicated to delivering a better total experience in aesthetics, dermatology and neurosciences. By working side by side with physicians and patients, Merz Neurosciences strives to deliver meaningful treatment options and a better patient experience in order to meet the needs of each person we serve. Merz Neurosciences is an important contributor to the U.S. neurosciences space, offering a well-balanced product portfolio that includes the neurotoxin Xeomin® (incobotulinumtoxinA), the anticholinergic Cuvposa™ (glycopyrrolate) Oral Solution and the Prolaryn™ family of products.

To learn more about Merz Neurosciences and their U.S. product portfolio, please visit XEOMIN® IMPORTANT CONSUMER SAFETY INFORMATION

Read the Medication Guide before you start receiving XEOMIN® (Zeo-min) and each time XEOMIN® is given to you as there may be new information. The risk information provided here is not comprehensive. To learn more:

• Talk to your health care provider or pharmacist

• Visit to obtain the FDA-approved product labeling

• Call 1-888-4-XEOMIN

Uses XEOMIN® is a prescription medicine that is injected into muscles and used to treat:

• increased muscle stiffness in the arm of adults with upper limb spasticity

• abnormal head position and neck pain in adults with cervical dystonia (CD)

• abnormal spasm of the eyelids (blepharospasm) in adults who have had prior treatment with onabotulinumtoxinA (BOTOX®)

It is not known whether XEOMIN® is safe or effective in children.


XEOMIN® may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems anytime (hours to week) after treatment with XEOMIN®:

Problems with swallowing, speaking, or breathing can happen within hours to weeks after an injection of XEOMIN® if the muscles that you use to breathe and swallow become weak. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with XEOMIN®.

• People with certain breathing problems may need to use muscles in their neck to help them breathe and may be at greater risk for serious breathing problems with XEOMIN®.

Download File:
02.09.2016-1 [ 0 KB ]

Press Contact

Merz North America

Emily Browder
Corporate Communications


Phone: +1 919.582.8114

Merz in the Americas

Merz has a direct presence in six countries in the Americas, as well as a network of selected professional distribution partners in South and Central America and the Caribbean. Merz in the Americas is headquartered in Raleigh, North Carolina, and has facilities in Mesa, Arizona, Franksville, Wisconsin as well as offices in Toronto, Canada, Mexico City, Bogotá, Colombia, São Paolo, Brazil and Buenos Aires, Argentina.

Merz Worldwide

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at

Media Contact – Global

Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466

Media Contact – North America

Merz North America, Inc.
Corporate Communications
Emily Browder
Phone: +1 919.582.8114